Metabolic risk status and second-generation antipsychotic drug selection: A retrospective study of commercially insured patients

Journal of Clinical Psychopharmacology

Volumn 29, Issue 1, 2009, Pages 26-32

  Morrato, Elaine H ^a,b,c   Cuffel, Brian ^d   Newcomer, John W ^e   Lombardo, Ilise ^d   Kamat, Siddhesh ^f   Barron, John ^f  

^a Children's Hospital Colorado   (United States)

^b Global Health and Health Disparities   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d PFIZER INC   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f HEALTHCORE INC   (United States)

Author keywords

Antipsychotic drugs; Diabetes; Dyslipidemia; Prescribing decisions

Indexed keywords

ARIPIPRAZOLE; CHOLESTEROL; GLUCOSE; LIPID; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE; NEUROLEPTIC AGENT;

ADULT; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CHOLESTEROL BLOOD LEVEL; CLINICAL DECISION MAKING; COHORT ANALYSIS; DEPRESSION; DIABETES MELLITUS; DRUG SUBSTITUTION; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; PRIORITY JOURNAL; PSYCHOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES; AGED; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL PRACTICE; MENTAL DISEASE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; MONITORING; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; CHOLESTEROL; COHORT STUDIES; FEMALE; HUMANS; MALE; MANAGED CARE PROGRAMS; MENTAL DISORDERS; METABOLIC SYNDROME X; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; RISK FACTORS; TRIGLYCERIDES; UNITED STATES; YOUNG ADULT;

EID: 62649139227     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31819294cb     Document Type: Article

References (39)

1. Colton C, Manderscheid R. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis. Apr 2006;3(2):A42.
2. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19-32.
3. Fagiolini A, Frank E, Scott J, et al. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord. 2005;7:424-430.
4. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1-93.
5. Lean ME, Pajonk FG. Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care. 2003;26:1597-1605.
6. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80:45-53.
7. Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA. 2007;298:1794-1796.
8. Druss BG, Bradford WD, Rosenheck R, et al. Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry. 2001;58:565-572.
9. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry. 1997;171:502-508.
10. Baxter D. The mortality experience of individuals on the Salford Psychiatric Case Register I. All-cause mortality. Br J Psychiatry. 1996;168:772-779.
11. Brown S, Birtwistle J, Roe L, et al. The unhealthy lifestyle of people with schizophrenia. Psychol Med. 1999;29:697-701.
12. Goff DC, Cather C, Evins AE, et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry. 2005;66:183-194.
13. Allison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry. 1999;60:215-220.
14. Chambers R, Krystal J, Self D. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry. 2001;50:71-83.
15. Keck PE, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy- associated weight gain. J Clin Psychiatry. 2003;64:1426-1435.
16. van Winkel R, van Os J, Celic I, et al. Psychiatric diagnosis as an independent risk factor for metabolic disturbances: results from a comprehensive, naturalistic screening program. J Clin Psychiatry. 2008;69:1319-1327.
17. U.S. Food and Drug Administration. Warning about hyperglycemia and atypical antipsychotic drugs. FDA Safety News [June 2004]: http://www. accessdata.fda.gov/scripts/cdrh/cfdocs/psn/transcript.cfm?show=28#4. Accessed February 12, 2007.
18. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry. 2001;46:273-281.
19. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002;159:561-566.
20. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65:267-272.
21. Haupt D. Differential metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol. 2006;16:S149-S155.
22. Meyer JM, Davis VG, Goff DC, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res. 2008;101:273-286.
23. Weiden P. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. J Clin Psychiatry. 2007;68:34-39.
24. Newcomer JW, Nasrallah HA, Loebel AD. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol. 2004;24:S1-6.
25. Buckley PF, Miller DD, Singer B, et al. Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res. 2005;79:281-288.
26. Morrato EH, Newcomer JW, Allen RR, et al. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. J Clin Psychiatry. 2008;69:316-322.
27. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
28. Sernyak MJ. Implementation of monitoring and management guidelines for second-generation antipsychotics. J Clin Psychiatry. 2007;68:14-18.
29. Druss BG. Improving medical care for persons with serious mental illness: challenges and solutions. J Clin Psychiatry. 2007;68:40-44.
30. Druss BG, von Esenwein S. Improving general medical care for persons with mental and addictive disorders: systematic review. Gen Hosp Psychiatry. 2006;28:145-153.
31. Marder S, Essock S, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161:1334-1349.
32. Barnett A, Mackin P, Chaudhry I, et al. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol. 2007;21:357-373.
33. Hassan M, Madhavan SS, Kalsekar ID, et al. Comparing adherence to and persistence with antipsychotic therapy among patients with bipolar disorder. Ann Pharmacother. 2007; 41:1812-1818.
34. Vanelli M, Coca-Perraillon M, Troxell-Dorgan A. Role of patient experience in atypical antipsychotic adherence: a retrospective data analysis. Clin Ther. 2007;29:2768-2773.
35. Meltzer HY. Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics. J Clin Psychiatry. 2001;62:35-39.
36. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull. 2004;30(2):193-217.
37. Milner K, Valenstein M. A comparison of guidelines for the treatment of schizophrenia. Psychiatr Serv. 2002;53(7):888-890.
38. Ketter T, Haupt D. Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice. Curr Med Res Opin. 2006;22:2345-2353.
39. Suppes T, McElroy S, Hirschfeld R. Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: a survey of 500 US psychiatrists. Psychopharmacol Bull. 2007;40:22-37.